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VIEWPOINT
ONLINE FIRST
Stemming the Global Trade in Falsified
and Substandard Medicines
Lawrence O. Gostin, JD
Gillian J. Buckley, MPH, PhD
Patrick W. Kelley, MD, DrPH
WHEN HIPPOCRATES ADVISED PHYSICIANS TOnever give a deadly drug, he assumed theywould know for sure that the medicinesthey prescribed were safe. Today, criminals
and unscrupulous manufacturers have permeated the
global pharmaceutical market, calling into question this
basic assumption of clinical practice. Between November
2012 and March 2013, an injectable drug compounded
under unhygienic conditions at the New England Com-
pounding Pharmacy was linked to more than 700 illnesses
and 50 deaths.1 In poor countries, where drug regulatory
oversight is weaker, the problem is worse, but blends with
the background noise of high mortality and strained health
systems. Only in rare cases, as when 120 Pakistanis died
after taking a carelessly made batch of isosorbide mononi-
trate, do people in low- and middle-income countries learn
of their vulnerability.2
The pharmaceutical trade is transnational, lucrative, and
extensive; the United Nations Office on Drugs and Crime
estimates the value of the illegal antimalarial drug market
in west Africa alone exceeds $400 million.3 These products
pose immense dangers. Falsified and substandard drugsmay
contain no active pharmaceutical ingredient or contain the
active ingredient at subtherapeutic doses. Poor-quality an-
timicrobial drugs are amajor problem in Southeast Asia and
sub-Saharan Africa,4,5 where they contribute to drug resis-
tance, reducing a drug’s effectiveness. Society must bear the
cost of developing alternate therapies. Poor-quality prod-
ucts increase health care costs, while causing patients to lose
confidence in the health system.
In a report released recently, an Institute of Medicine ex-
pert committee examined the causes of, and solutions to,
the problem of falsified and substandard drugs in the United
States and globally.6
A Common Language
At the heart of the problem is a lack of a common lan-
guage. Some emerging manufacturing nations and civil so-
ciety groups object to using the broad descriptor counter-
feit for all poor-quality drugs. In a narrow sense, counterfeit
products are only those that infringe on a registered trade-
mark. Stakeholders concerned with access to generic medi-
cines fear that action against counterfeit drugs wouldmean
stricter enforcement of intellectual property rights, thereby
reducing the availability of inexpensive generics.
To avoid confusion, the term counterfeit should be used
only to describe a trademark infringement. Medicines pos-
ing a public health concern include 2 overlapping catego-
ries. A falsified drug misrepresents the product’s identity,
source, or both. A substandard drug fails to meet national
specifications in accepted pharmacopoeia or the manufac-
turer’s dossier. This language frames falsified and substan-
dardmedicines exclusively as a public health problem. Con-
sistent use of these termswould facilitate clear communication
among regulators, police, and industry. A common lan-
guage would allow for more accurate measurement of the
scope and trends at the national and global levels.
Pharmacovigilance
There are no reliable estimates of the global burden of fal-
sified and substandard medicines. The World Health Or-
ganization has a promising pilot approach to train regula-
tors for drug quality surveillance in 10 developing countries,
using rapid alert forms to identify dangerous products and
link incidents across different countries.Governments should
establish or strengthen systems to detect and monitor sub-
standard and falsifiedmedicines, integrating pharmacovigi-
lance into routine national surveillance. Quality surveil-
lancewould improve understanding of the types of products
compromised and the extent of the trade.
Track and Trace
A porous global supply chain allows good medicines to be
diverted to the illicit market and poor-quality medicines to
enter the legal one. Securing themedicines’ chain of custody
would protect the drug supply. Track and trace systems em-
power stakeholders to know a drug’s location and authen-
ticity throughout the distribution chain. A federal track and
trace systemwould enable companies to followauniformstan-
dardwithout state variations. Therefore, Congress should au-
thorize and fund the Food and Drug Administration (FDA)
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to establish a mandatory track and trace system. In the in-
terim, the FDA should convene stakeholders to promote vol-
untary track and trace for all supply chain actors. FDA ac-
tion would protect the US consumer, while building
momentum for tighter medicine controls internationally.
Wholesale Licensing
Secondarywholesalers and state standards varywidely. States
license wholesalers, with standards varying widely. Unscru-
pulous firms seek out states with weak oversight. Because
the wholesale market is national, weaknesses in one state’s
system threaten the others. To rectify this problem, states
should grant licenses only to wholesalers meeting the Na-
tional Association of Boards of Pharmacy accreditation stan-
dards. The FDA could promote openness in the licensing
process by creating a public database to share information
on suspended and revoked wholesale licenses. Tight ac-
creditation and transparent information sharing would help
thwart irresponsible wholesalers.
Quality Manufacturing
Drug production depends on good manufacturing prac-
tices andquality control. Small- andmedium-sized drug com-
panies in developing countries lack the infrastructure, equip-
ment, and staff necessary to meet international standards.
These firms do not operate on a scale that allows them to
recover the costs of running amodern factory, and they have
few avenues to raise capital from national banks. TheWorld
Bank’s International Finance Group and the US govern-
ment’s Overseas Private Investment Corporation should in-
vest in pharmaceutical manufacturing in developing coun-
tries. Companies that avail themselves of loans can raise their
standards, thus providing inexpensive, quality medicines in
a market starved for them.
Drug Retail
The private sector also has a role in improving drug retail
in developing countries, where the poor often have no choice
but to purchase drugs from unlicensed shops or open-air
markets. These markets violate many basic principles of re-
sponsible pharmacy practice: tablets are sold loose, blister
packs cut apart, and secure storage is rare. Shopkeepers have
no training in the proper handling or buying of medicines.
Inasmuch as development finance organizations can help
good-faith manufacturers, governments can use training,
franchising, and accreditation schemes to create better drug
retail. National pharmacy councils can improve workforce
efficiency by assigning some pharmacy tasks to techni-
cians, a process known as task shifting. Vocational training
in dispensing medicines, combined with incentives to re-
tain trained staff in rural areas and slums, would improve
medicines’ retail in the poorest countries.
International Code of Practice
National regulatory authorities have the final responsibil-
ity for a country’s drug supply: preventing falsified and sub-
standard drugs from entering the market, detecting them
when they do, and punishing unscrupulous actors. How-
ever, no country acting alone can protect its inhabitants from
falsified and substandard medicines.
TheWorldHealthOrganization has the constitutional au-
thority to promulgate an international code of practice, a
type of voluntary soft law, pertaining to falsified and sub-
standard medicines. This code would catalyze stakeholder
action and coordinate regulatory, customs, and law enforce-
ment agencies. The World Health Assembly, in partner-
ship with United Nations Office on Drugs and Crime and
theWorld Customs Organization, should develop the code
using an open and inclusive process. The code would offer
guidance on standard terminology, surveillance, regula-
tion, and law enforcement. It would set clear targets, moni-
tor results, andmobilize resources and technical assistance
for low- and middle-income countries. Most importantly,
the codewould promote international cooperation andmul-
tisector action against the criminal syndicates that poison
the world’s medicine supply.
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